Pharmaceutical major Lupin on Thursday reported a 47.54% year-on-year rise in consolidated net profit to ₹807 crore for the quarter ended March. Net sales grew by 33.96% to ₹4,091 crore. The Europe and US formulations business (including IP), accounting for 57% of the total sales, jumped 58% to ₹2,312 crore, while Indian formulations' sales rose by 14.7% to ₹761 crore.